ArticleClinical nephrology2025
Prediction and phenotyping of long COVID in kidney transplant recipients: A cross-sectional study.
Article in Clinical nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Shadows of infection: Post-coronavirus disease condition and outcome patterns in patients receiving dialysis and kidney transplant recipients.World journal of nephrology · 2026Review
- Long COVID sequelae in heart transplant recipients.JHLT open · 2026Article
- Obesity and Nutritional Vulnerability in long COVID: A Neuroinflammatory and Cognitive Perspective.Current nutrition reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim was to describe the epidemiology, phenotyping, and risk factors of long COVID (LC) in a well-defined cohort of kidney transplant recipients (KTRs) using a novel LC diagnostic method based on self-reported symptoms. MATERIALS AND
methodsWe conducted a cross-sectional study using an electronic survey to inquire about persisting symptoms following COVID-19. KTRs who survived COVID-19 up to February 8, 2023, were considered for inclusion, and 596 KTRs were enrolled. A brief 35-question screening questionnaire was used. A novel statistical approach based on the factor analysis method was used to make LC diagnosis and identify its clinical phenotypes.
resultsLC was identified in 33.7% of KTRs who responded to the survey. Male sex (OR 0.69, 95% CI 0.48 - 1.0, p = 0.047), more severe COVID-19 (OR 2.48, 95% CI 1.58 - 3.92, p < 0.001), higher body mass index (OR 1.04, 95% CI 1.0 - 1.08, p = 0.031), and corticosteroids (OR 2.8, 95% CI 1.23 - 7.09, p = 0.02) were independently associated with LC development. Eight LC phenotypes were identified based on symptom clustering: fatigue (32.4% of all KTRs), psychiatric (15.9%), cardiovascular (6%), ophthalmic (13.8%), cognitive (17.8%), fibromyalgia-like (11.1%), integumental (10.6%), and malnutritional (6%). The rate of LC was similar in those who had COVID-19 less/more than a year since responding to the survey.
conclusionA novel method for determining LC diagnosis and its phenotyping was used in a large cohort of KTRs, which showed that a third of KTRs who responded to the survey developed LC after COVID-19. This method may improve diagnosis and future research of LC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.